Axtria, a global leader in cloud software and data analytics for the life sciences industry, has been recognized for six technologies in the Gartner® Hype Cycle™ for Life Sciences (LS) Commercial Operations, 2024. This Hype Cycle tracks trends, maturity levels and adoption rates of key technologies, guiding CIOs in prioritizing technology strategy and investments.
“We’re honored to have been recognized yet again for six technologies in the 2024 Gartner® Hype CycleTM for Life Science Commercial Operations,” said Jaswinder “Jassi” Chadha, Axtria President and CEO. “We believe this underscores our commitment to helping clients improve patient outcomes by connecting the right therapies to the right patients at the right time in the most efficient and innovative ways. We’re proud our innovations are helping life science companies complete the journey from data to insights to action.”
Axtria was recognized in the following categories:
- Augmented Analytics in LS
- Personalization Engines in LS
- D&A Platforms in Commercial LS
- AI in Commercial Operations
- Sales Performance Management in LS
- Advanced Decision Support for Sales
Axtria provides complimentary access to the full “Hype Cycle for Life Science Commercial Operations, 2024” report, which can be found here.
Gartner Disclaimer
Gartner, Hype Cycle for Life Science Commercial Operations, 2024, Animesh Gandhi, 13 August 2024.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally; Hype Cycle is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product, or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner’s research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.